Literature DB >> 21885727

The burden of disease in pediatric non-cystic fibrosis bronchiectasis.

Nitin Kapur1, I Brent Masters2, Peter Newcombe3, Anne B Chang4.   

Abstract

BACKGROUND: The burden of disease in children with non-cystic fibrosis (non-CF) bronchiectasis is unknown. Our study aimed to identify the determinants of quality of life (QOL) and parental mental health in this group of patients and their parents and to evaluate the effect of exacerbations on these parameters.
METHODS: Parents of 69 children (median age 7 years) with non-CF bronchiectasis prospectively completed two questionnaires (parent-proxy cough-specific quality of life [PC-QOL] and the Depression, Anxiety, and Stress Scale [DASS]) at stable and exacerbation states. Data on clinical, investigational, and lung function parameters were also collected.
RESULTS: During the stable state, the median interquartile range (IQR) PC-QOL score was 6.5 (5.3-6.9) and the DASS 21-item questionnaire score was 6 (0-20). Being of a young age correlated with a worse QOL (r(5) = 0.242, P = .04) but radiologic extent, lung function, underlying cause, environmental tobacco smoke exposure, and chronic upper-airway disease did not influence these scores. Exacerbations caused significant worsening in the PC-QOL scores (median [IQR], 4.6 [3.8-5.4]; P = .001) and DASS scores (median [IQR], 22 [9-42]; P < .001; 38% with elevated anxiety, 54% with abnormal depression/stress scores during exacerbation). The presence of viral infection, hypoxia, and hospitalization did not influence the exacerbation PC-QOL and DASS scores.
CONCLUSIONS: There is a significant burden of disease, especially during exacerbation, on parents of children with bronchiectasis. Prevention, early detection, and appropriate treatment of exacerbations are likely to reduce psychologic morbidity in this group.

Entities:  

Mesh:

Year:  2011        PMID: 21885727     DOI: 10.1378/chest.11-0679

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  28 in total

1.  The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial.

Authors:  Kerry-Ann F O'Grady; Anne B Chang; Allan Cripps; Edward K Mulholland; Heidi Smith-Vaughan; Nicholas Wood; Margaret Danchin; Ruth Thornton; Andrew Wilson; Paul J Torzillo; Peter M Morris; Peter Richmond; Sheree Rablin; Daniel Arnold; Ann Connor; Vikas Goyal; Tanya Stoney; Kirsten Perrett; Keith Grimwood
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

2.  Longitudinal study of quality of life among children with acute respiratory infection and cough.

Authors:  Yolanda G Lovie-Toon; Anne B Chang; Peter A Newcombe; Dimitrios Vagenas; Sophie Anderson-James; Benjamin J Drescher; Michael E Otim; Kerry-Ann F O'Grady
Journal:  Qual Life Res       Date:  2018-01-22       Impact factor: 4.147

3.  Respiratory exacerbations in indigenous children from two countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis.

Authors:  Gregory J Redding; Rosalyn J Singleton; Patricia C Valery; Hayley Williams; Keith Grimwood; Peter S Morris; Paul J Torzillo; Gabrielle B McCallum; Lori Chikoyak; Robert C Holman; Anne B Chang
Journal:  Chest       Date:  2014-09       Impact factor: 9.410

4.  Noncystic Fibrosis Bronchiectasis: Evaluation of an Extensive Diagnostic Protocol in Determining Pediatric Lung Disease Etiology.

Authors:  Nike I Beckeringh; Niels W Rutjes; Joost van Schuppen; Taco W Kuijpers
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-12-11       Impact factor: 1.349

5.  Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Colin F Robertson; Andrew C Wilson; Peter P van Asperen; Kerry-Ann F O'Grady; Theo P Sloots; Paul J Torzillo; Emily J Bailey; Gabrielle B McCallum; Ian B Masters; Catherine A Byrnes; Mark D Chatfield; Helen M Buntain; Ian M Mackay; Peter S Morris
Journal:  Trials       Date:  2012-08-31       Impact factor: 2.279

Review 6.  Dual antibiotics for bronchiectasis.

Authors:  Lambert M Felix; Seamus Grundy; Stephen J Milan; Ross Armstrong; Haley Harrison; Dave Lynes; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2018-06-11

7.  Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Andrew C Wilson; Peter P van Asperen; Catherine A Byrnes; Kerry-Ann F O'Grady; Theo P Sloots; Colin F Robertson; Paul J Torzillo; Gabrielle B McCallum; Ian B Masters; Helen M Buntain; Ian M Mackay; Jacobus Ungerer; Joanne Tuppin; Peter S Morris
Journal:  Trials       Date:  2013-02-20       Impact factor: 2.279

Review 8.  Head-to-head trials of antibiotics for bronchiectasis.

Authors:  Axel Kaehne; Stephen J Milan; Lambert M Felix; Emer Sheridan; Paul A Marsden; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2018-09-05

Review 9.  Continuous versus intermittent antibiotics for bronchiectasis.

Authors:  Tim Donovan; Lambert M Felix; James D Chalmers; Stephen J Milan; Alexander G Mathioudakis; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2018-06-03

Review 10.  Macrolide antibiotics for bronchiectasis.

Authors:  Carol Kelly; James D Chalmers; Iain Crossingham; Nicola Relph; Lambert M Felix; David J Evans; Stephen J Milan; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.